Slate - Shared Neoantigen Immunotherapy
From Our Pipeline
Our second product candidate, SLATE, utilizes the same neoantigen delivery system as GRANITE but contains a fixed set of neoantigens that are shared across a subset of cancer patients rather than neoantigens unique to an individual patient, providing us with an off-the-shelf alternative to GRANITE. SLATE is being evaluated in the Phase 2 portion of a Phase I/2 clinical study in combination with checkpoint inhibitors for the treatment of non-small cell lung cancer in patients with relevant KRAS mutations who have progressed on prior immunotherapy, and for cancer types where a relevant TP53 mutation exists.
-
Most popular related searches
Details
The routine clinical biopsy used to identify personalized patient mutations can also identify patients that have common mutations within their tumor from commercially available genomic panel sequencing. These common driver mutations have been shown to produce shared neoantigens as identified by Gritstone’s EDGE platform in a subset of patients. Similar to patient-specific neoantigens, shared neoantigens are a class of immune targets that present mutated peptides on the surface of the tumor cell. Because these neoantigens are shared, an “off-the-shelf” therapy may be able to treat additional patients across multiple tumor types.
Customer reviews
No reviews were found for Slate - Shared Neoantigen Immunotherapy. Be the first to review!